

Jon Stoessl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7075033/publications.pdf>

Version: 2024-02-01

279
papers

23,671
citations

13827

67
h-index

8835

145
g-index

290
all docs

290
docs citations

290
times ranked

17429
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. <i>Neuron</i> , 2004, 44, 601-607.	3.8	2,653
2	A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. <i>Annals of Neurology</i> , 2003, 54, 403-414.	2.8	1,450
3	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006, 59, 459-466.	2.8	890
4	Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease. <i>Science</i> , 2001, 293, 1164-1166.	6.0	885
5	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003, 54, 93-101.	2.8	820
6	DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS. <i>Lancet, The</i> , 1986, 328, 245-247.	6.3	727
7	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
8	Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 811-813.	2.2	545
9	Safety and tolerability of intraputamenal delivery of CERE-120 (adeno-associated virus serotype) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Neurology, The</i> , 2008, 7, 400-408.	4.9	529
10	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 493-503.	2.8	515
11	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , 2015, 132, 96-168.	2.8	379
12	Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. <i>Brain</i> , 2004, 127, 2747-2754.	3.7	361
13	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. , 2000, 47, 493.		329
14	Neural transplantation for the treatment of Parkinson's disease. <i>Lancet Neurology, The</i> , 2003, 2, 437-445.	4.9	322
15	Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. <i>Nature</i> , 1985, 317, 246-248.	13.7	309
16	Dopamine release in human ventral striatum and expectation of reward. <i>Behavioural Brain Research</i> , 2002, 136, 359-363.	1.2	303
17	DCTN1 mutations in Perry syndrome. <i>Nature Genetics</i> , 2009, 41, 163-165.	9.4	285
18	Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	4.5	272

#	ARTICLE	IF	CITATIONS
19	DNAJC13 mutations in Parkinson disease. <i>Human Molecular Genetics</i> , 2014, 23, 1794-1801.	1.4	258
20	Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease. <i>Archives of General Psychiatry</i> , 2010, 67, 857.	13.8	244
21	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. <i>Brain</i> , 2005, 128, 2777-2785.	3.7	242
22	Bilateral human fetal striatal transplantation in Huntingtonâ€™s disease. <i>Neurology</i> , 2002, 58, 687-695.	1.5	234
23	Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. <i>Brain</i> , 2009, 132, 2970-2979.	3.7	223
24	Tenâ€™year followâ€™up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	2.2	221
25	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. <i>Annals of Neurology</i> , 2001, 49, 298-303.	2.8	205
26	Age-dependent decline of dopamine D1 receptors in human brain: A PET study. , 1998, 30, 56-61.		203
27	Ageâ€™specific progression of nigrostriatal dysfunction in Parkinson's disease. <i>Annals of Neurology</i> , 2011, 69, 803-810.	2.8	197
28	The PARK8 Locus in Autosomal Dominant Parkinsonism: Confirmation of Linkage and Further Delineation of the Disease-Containing Interval. <i>American Journal of Human Genetics</i> , 2004, 74, 11-19.	2.6	195
29	Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinsonâ€™s disease. <i>Brain</i> , 2019, 142, 512-525.	3.7	194
30	Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. <i>Experimental Neurology</i> , 2003, 184, 68-79.	2.0	166
31	The placebo effect in neurological disorders. <i>Lancet Neurology</i> , The, 2002, 1, 85-91.	4.9	164
32	Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinsonâ€™s disease: a multi-country Delphi-panel approach. <i>Current Medical Research and Opinion</i> , 2018, 34, 2063-2073.	0.9	152
33	Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. <i>Movement Disorders</i> , 2003, 18, 157-162.	2.2	151
34	The effects of exercise on cognition in Parkinsonâ€™s disease: a systematic review. <i>Translational Neurodegeneration</i> , 2014, 3, 5.	3.6	139
35	The placebo effect in Parkinson's disease. <i>Trends in Neurosciences</i> , 2002, 25, 302-306.	4.2	138
36	Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. <i>Brain</i> , 2011, 134, 3290-3298.	3.7	133

#	ARTICLE	IF	CITATIONS
37	Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. <i>Lancet, The</i> , 2014, 384, 532-544.	6.3	129
38	Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). <i>Movement Disorders</i> , 2004, 19, 622-629.	2.2	127
39	PET Study of [18F]6-Fluoro-l-Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium. <i>American Journal of Psychiatry</i> , 2002, 159, 768-774.	4.0	123
40	Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. <i>Annals of Neurology</i> , 2007, 62, 468-474.	2.8	121
41	Placebo mechanisms and reward circuitry: clues from Parkinson's disease. <i>Biological Psychiatry</i> , 2004, 56, 67-71.	0.7	119
42	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 869-877.	1.1	119
43	Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence from a New Modeling Approach to PET 18F-Fluorodopa Data. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 232-239.	2.4	117
44	SCA-2 presenting as parkinsonism in an Alberta family. <i>Neurology</i> , 2002, 59, 1625-1627.	1.5	113
45	Progression of dopaminergic dysfunction in a <i>LRRK2</i> kindred. <i>Neurology</i> , 2008, 71, 1790-1795.	1.5	112
46	Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. <i>Brain</i> , 2004, 127, 888-899.	3.7	106
47	PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. <i>Neurology</i> , 2009, 72, 1211-1216.	1.5	104
48	Dopamine turnover increases in asymptomatic <i>LRRK2</i> mutations carriers. <i>Movement Disorders</i> , 2010, 25, 2717-2723.	2.2	103
49	Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. <i>Movement Disorders</i> , 2006, 21, 1457-1461.	2.2	102
50	Advances in imaging in Parkinson's disease. <i>Lancet Neurology, The</i> , 2011, 10, 987-1001.	4.9	99
51	Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1891-1900.	2.2	99
52	Familial parkinsonism: Study of original Sagami-hara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 300-306.	1.1	98
53	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. <i>Lancet Neurology, The</i> , 2017, 16, 351-359.	4.9	96
54	Pallidonigral TDP-43 pathology in Perry syndrome. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 281-286.	1.1	89

#	ARTICLE	IF	CITATIONS
55	Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 301-313.	1.5	89
56	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017, 32, 181-192.	2.2	88
57	PET Study of the Effects of Valproate on Dopamine D2Receptors in Neuroleptic- and Mood-Stabilizer-Naive Patients With Nonpsychotic Mania. <i>American Journal of Psychiatry</i> , 2002, 159, 1718-1723.	4.0	86
58	Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. <i>Neurology</i> , 2012, 78, 649-657.	1.5	85
59	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. <i>Annals of Neurology</i> , 2001, 49, 298-303.	2.8	85
60	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video-based analysis. <i>Movement Disorders</i> , 2009, 24, 336-343.	2.2	84
61	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 57, 248.e7-248.e12.	1.5	83
62	Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 869-876.	2.4	81
63	Nigrostriatal dopamine system and motor lateralization. <i>Behavioural Brain Research</i> , 2000, 112, 63-68.	1.2	76
64	Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. <i>Brain</i> , 2006, 129, 1050-1058.	3.7	76
65	Effect of electroconvulsive therapy on brain 5-HT ₂ receptors in major depression. <i>British Journal of Psychiatry</i> , 2010, 196, 474-479.	1.7	76
66	Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide. <i>Brain Research</i> , 1990, 534, 1-7.	1.1	74
67	Phosphorylated α -synuclein in Parkinson's disease: correlation depends on disease severity. <i>Acta Neuropathologica Communications</i> , 2015, 3, 7.	2.4	74
68	Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. <i>Stroke</i> , 1985, 16, 734-736.	1.0	72
69	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. <i>Annals of Neurology</i> , 2017, 81, 46-57.	2.8	72
70	Invited Article: Functional imaging in Parkinson disease. <i>Neurology</i> , 2008, 70, 1478-1488.	1.5	70
71	Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease. <i>JAMA Neurology</i> , 2021, 78, 1262.	4.5	70
72	VMAT2 binding is elevated in dopa-responsive dystonia: Visualizing empty vesicles by PET. <i>Synapse</i> , 2003, 49, 20-28.	0.6	69

#	ARTICLE	IF	CITATIONS
73	Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. <i>Neurology</i> , 2006, 66, 1588-1590.	1.5	69
74	Understanding the Placebo Effect: Contributions from Neuroimaging. <i>Molecular Imaging and Biology</i> , 2007, 9, 176-185.	1.3	69
75	Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [¹¹ C]-raclopride and positron-emission tomography. <i>Neurology</i> , 1998, 50, 1028-1032.	1.5	67
76	[¹¹ C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. <i>Brain</i> , 2003, 126, 2648-2655.	3.7	63
77	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020, 10, 875-891.	1.5	63
78	Dihydrotrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. <i>Annals of Neurology</i> , 2008, 63, 388-394.	2.8	62
79	PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins. <i>Movement Disorders</i> , 2017, 32, 1016-1024.	2.2	62
80	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. <i>Movement Disorders</i> , 2019, 34, 1406-1422.	2.2	62
81	Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. <i>Journal of Neural Transmission</i> , 2000, 107, 49-57.	1.4	61
82	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. <i>Neurology</i> , 2013, 81, 1322-1331.	1.5	60
83	<i>DNAJC12</i> and dopa-responsive nonprogressive parkinsonism. <i>Annals of Neurology</i> , 2017, 82, 640-646.	2.8	60
84	The NK ₃ tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. <i>British Journal of Pharmacology</i> , 1988, 94, 285-287.	2.7	59
85	Neuroimaging in Parkinson's Disease. <i>Neurotherapeutics</i> , 2011, 8, 72-81.	2.1	59
86	Positron emission tomography after fetal transplantation in Huntington's disease. <i>Annals of Neurology</i> , 2005, 58, 331-337.	2.8	57
87	The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. <i>Lancet Neurology</i> , The, 2018, 17, 309-316.	4.9	57
88	Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists. <i>Psychopharmacology</i> , 1989, 98, 372-379.	1.5	56
89	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. <i>Neurogenetics</i> , 2014, 15, 23-30.	0.7	56
90	Glucose utilization: still in the synapse. <i>Nature Neuroscience</i> , 2017, 20, 382-384.	7.1	56

#	ARTICLE	IF	CITATIONS
91	Unilateral pallidotomy for reduction of parkinsonian pain. <i>Journal of Neurosurgery</i> , 1999, 91, 198-201.	0.9	55
92	Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. <i>Brain Research</i> , 1991, 565, 254-262.	1.1	54
93	Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1151-1159.	2.4	52
94	The Biochemical Bases for Reward. <i>Evaluation and the Health Professions</i> , 2002, 25, 387-398.	0.9	52
95	Visualizing vesicular dopamine dynamics in Parkinson's disease. <i>Synapse</i> , 2009, 63, 713-716.	0.6	50
96	Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an <i>in vivo</i> imaging study. <i>Journal of Neurochemistry</i> , 2009, 109, 85-92.	2.1	50
97	Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. , 2013, 140, 306-318.		50
98	Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 359-365.	2.2	48
99	Localization of striatal and nigral tachykinin receptors in the rat. <i>Brain Research</i> , 1994, 646, 13-18.	1.1	47
100	Etiology of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, S10-S18.	0.3	47
101	Lack of Regional Selectivity During the Progression of Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1920-5.	4.9	47
102	Positron emission tomography in premotor Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S421-S424.	1.1	46
103	Dopamine transporter PET in normal aging: Dopamine transporter decline and its possible role in preservation of motor function. <i>Synapse</i> , 2010, 64, 146-151.	0.6	46
104	Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki. <i>Parkinsonism and Related Disorders</i> , 2001, 7, 305-309.	1.1	45
105	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019, 9, 31-61.	1.5	45
106	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. <i>PLoS ONE</i> , 2012, 7, e43099.	1.1	44
107	Pallidotomy for tardive dyskinesia. <i>Lancet, The</i> , 1997, 349, 777-778.	6.3	43
108	Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. <i>Neuroscience</i> , 2003, 116, 307-314.	1.1	43

#	ARTICLE	IF	CITATIONS
109	Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. <i>Molecular Brain Research</i> , 2005, 134, 24-33.	2.5	43
110	COVID-19 and selective vulnerability to Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 719.	4.9	43
111	Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy. <i>Brain Research</i> , 1989, 495, 20-30.	1.1	42
112	Daytime somnolence in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2001, 7, 283-286.	1.1	42
113	<i>DNAJC13</i> genetic variants in parkinsonism. <i>Movement Disorders</i> , 2015, 30, 273-278.	2.2	42
114	Cerebral metabolism of glucose in benign hereditary chorea. <i>Movement Disorders</i> , 1986, 1, 33-44.	2.2	40
115	Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. <i>Psychopharmacology</i> , 1987, 93, 336-42.	1.5	40
116	Pharmacological characterization of the behavioral syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. <i>Brain Research</i> , 1990, 517, 111-116.	1.1	40
117	Autosomal dominant dystonia-plus with cerebral calcifications. <i>Neurology</i> , 2006, 67, 620-625.	1.5	40
118	Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies. <i>Movement Disorders</i> , 2021, 36, 1781-1791.	2.2	40
119	Cerebrospinal fluid amyloid β and tau in <i>LRRK2</i> mutation carriers. <i>Neurology</i> , 2012, 78, 55-61.	1.5	39
120	Neuroimaging in Parkinson's disease: from pathology to diagnosis. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S55-S59.	1.1	39
121	Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes. <i>Prostaglandins</i> , 1977, 14, 819-827.	1.2	38
122	Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study. <i>Movement Disorders</i> , 2018, 33, 1945-1950.	2.2	37
123	Absence of Mutations in Superoxide Dismutase and Catalase Genes in Patients With Parkinson's Disease. <i>Archives of Neurology</i> , 1995, 52, 1160-1163.	4.9	36
124	Rett Syndrome: Investigation of Nine Patients, including PET Scan. <i>Canadian Journal of Neurological Sciences</i> , 2002, 29, 345-357.	0.3	36
125	Is Axonal Degeneration a Key Early Event in Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2016, 6, 703-707.	1.5	36
126	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology</i> , The, 2006, 5, 200-202.	4.9	35

#	ARTICLE	IF	CITATIONS
127	Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. <i>Neuroscience Letters</i> , 1987, 80, 321-326.	1.0	34
128	DJ-1 and α -SYN in LRRK2 CSF do not correlate with striatal dopaminergic function. <i>Neurobiology of Aging</i> , 2012, 33, 836.e5-836.e7.	1.5	34
129	Gender differences in Parkinson's disease depression. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 93-97.	1.1	34
130	Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. <i>Movement Disorders</i> , 2018, 33, 1213-1227.	2.2	34
131	(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM. <i>Lancet, The</i> , 1985, 326, 1330-1331.	6.3	33
132	Age and severity of nigrostriatal damage at onset of Parkinson's disease. <i>Synapse</i> , 2003, 47, 152-158.	0.6	33
133	The biochemical bases of the placebo effect. <i>Science and Engineering Ethics</i> , 2004, 10, 143-150.	1.7	33
134	<i>In-vivo</i> Measurement of LDOPA Uptake, Dopamine Reserve and Turnover in the Rat Brain Using [¹⁸ F]FDOPA PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 59-66.	2.4	33
135	Nemaline Myopathy With Associated Cardiomyopathy. <i>Archives of Neurology</i> , 1985, 42, 1084.	4.9	32
136	Response to Heat Pain Stimulation in Idiopathic Parkinson's Disease. <i>Pain Medicine</i> , 2010, 11, 834-840.	0.9	32
137	Behavioral Deficits and Striatal DA Signaling in LRRK2 p.G2019S Transgenic Rats: A Multimodal Investigation Including PET Neuroimaging. <i>Journal of Parkinson's Disease</i> , 2014, 4, 483-498.	1.5	32
138	Win-Concurrent Sensory Cues Can Promote Riskier Choice. <i>Journal of Neuroscience</i> , 2018, 38, 10362-10370.	1.7	32
139	Environmental Exposures in Elderly Canadians With Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1995, 22, 232-234.	0.3	30
140	Neuroimaging in the early diagnosis of neurodegenerative disease. <i>Translational Neurodegeneration</i> , 2012, 1, 5.	3.6	30
141	The Nature of Progression in Parkinson's Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling. <i>PLoS ONE</i> , 2013, 8, e76595.	1.1	30
142	Glucose Use Correlations: A Matter of Inference. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1986, 6, 511-512.	2.4	29
143	A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. <i>NeuroReport</i> , 1997, 8, 669-672.	0.6	29
144	Clustering of Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1057-60.	4.9	29

#	ARTICLE	IF	CITATIONS
145	A family with parkinsonism, essential tremor, restless legs syndrome, and depression. <i>Neurology</i> , 2011, 76, 1623-1630.	1.5	29
146	Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal) and Related Disorders, 2001, 7, 81-88.	1.1	27
147	Willing oneself better on placebo"effective in its own right. <i>Lancet</i> , 2004, 364, 227-228.	6.3	27
148	Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 539-541.	1.1	27
149	DCTN1 p.K56R in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 56-61.	1.1	27
150	Movement Disorders in the World of COVID-19. <i>Movement Disorders</i> , 2020, 35, 709-710.	2.2	27
151	Neuroimaging: Current role in detecting pre-motor Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 634-643.	2.2	26
152	Dopamine D1A receptor function in a rodent model of tardive dyskinesia. <i>Neuroscience</i> , 2000, 101, 629-635.	1.1	24
153	The placebo response as a reward mechanism. <i>Seminars in Pain Medicine</i> , 2005, 3, 37-42.	0.4	24
154	Etiology of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, S5-S12.	0.3	23
155	Parkinson's disease: imaging update. <i>Current Opinion in Neurology</i> , 2002, 15, 477-482.	1.8	23
156	Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. <i>NeuroImage: Clinical</i> , 2018, 19, 652-660.	1.4	23
157	Tremor induced by thalamic deep brain stimulation in patients with complex regional facial pain. <i>Movement Disorders</i> , 2004, 19, 933-936.	2.2	22
158	Biomarkers for trials of neuroprotection in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 71-85.	2.2	22
159	Optimizing diagnosis in Parkinson's disease: Radionuclide imaging. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S47-S51.	1.1	22
160	Effects of neurotensin in a rodent model of tardive dyskinesia. <i>Neuropharmacology</i> , 1995, 34, 457-462.	2.0	21
161	Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. <i>Neuroscience</i> , 2002, 112, 851-859.	1.1	21
162	Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. <i>Progress in Brain Research</i> , 2010, 184, 177-192.	0.9	21

#	ARTICLE	IF	CITATIONS
163	Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. <i>NeuroImage: Clinical</i> , 2019, 23, 101856.	1.4	21
164	Scans without evidence of dopamine deficiency: The triumph of careful clinical assessment. <i>Movement Disorders</i> , 2010, 25, 529-530.	2.2	20
165	Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. <i>EJNMMI Research</i> , 2013, 3, 69.	1.1	20
166	Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. <i>Movement Disorders</i> , 2014, 29, 1684-1687.	2.2	20
167	Regression Model for Predicting Dissociations of Regional Cerebral Glucose Metabolism in Individuals at Risk for Huntington's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1986, 6, 756-762.	2.4	19
168	Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity. <i>Synapse</i> , 2000, 37, 171-178.	0.6	19
169	The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. <i>Translational Neurodegeneration</i> , 2017, 6, 4.	3.6	19
170	The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. <i>Movement Disorders</i> , 1993, 8, 445-452.	2.2	18
171	Novel spatial analysis method for PET images using 3D moment invariants: Applications to Parkinson's disease. <i>NeuroImage</i> , 2013, 68, 11-21.	2.1	18
172	Movement Disorders in the World of COVID-19. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 355-356.	0.8	18
173	The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation. <i>Psychopharmacology</i> , 1988, 95, 502-6.	1.5	17
174	Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders. <i>Journal of Psychopharmacology</i> , 1989, 3, 99-120.	2.0	17
175	Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat. <i>Brain Research</i> , 1991, 558, 289-295.	1.1	17
176	Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone. <i>European Journal of Pharmacology</i> , 1994, 259, 301-303.	1.7	17
177	Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. , 1996, 24, 256-261.		17
178	[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. <i>Movement Disorders</i> , 2002, 17, 789-794.	2.2	17
179	Functional imaging studies of non-motoric manifestations of Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S13-S16.	1.1	17
180	Central administration of the neurotensin receptor antagonist sr48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. <i>Neuroscience</i> , 2003, 119, 547-555.	1.1	16

#	ARTICLE	IF	CITATIONS
181	Gene therapy for Parkinson's disease: a step closer?. Lancet, The, 2014, 383, 1107-1109.	6.3	16
182	DATâ€SPECT diagnoses dopamine depletion, but not PD. Movement Disorders, 2014, 29, 1705-1706.	2.2	16
183	Editors' Note: The 200th <scp>A</scp>nniversary of the <scp>S</scp>haking <scp>P</scp>alsy. Movement Disorders, 2017, 32, 1-1.	2.2	16
184	Gene therapy for Parkinson's disease: early data. Lancet, The, 2007, 369, 2056-2058.	6.3	15
185	Potential therapeutic targets for Parkinson's disease. Expert Opinion on Therapeutic Targets, 2008, 12, 425-436.	1.5	15
186	In vivo dopaminergic and serotonergic dysfunction in <i>DCTN1</i> gene mutation carriers. Movement Disorders, 2014, 29, 1197-1201.	2.2	15
187	Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). Current Opinion in Neurology, 1998, 11, 327-333.	1.8	15
188	Imaging striatal dopaminergic function in <i>Phospholipase A2 Group VI</i>â€related parkinsonism. Movement Disorders, 2012, 27, 1698-1699.	2.2	14
189	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. Movement Disorders Clinical Practice, 2014, 1, 67-69.	0.8	14
190	A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. Movement Disorders, 2016, 31, 405-409.	2.2	14
191	Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. PLoS ONE, 2018, 13, e0206607.	1.1	14
192	<i>Movement Disorders</i>: New Faces, Same Journal. Movement Disorders, 2020, 35, 1-2.	2.2	14
193	Weeding through the haze: a survey on cannabis use among people living with Parkinsonâ€™s disease in the US. Npj Parkinson's Disease, 2021, 7, 21.	2.5	14
194	Effects of ageing on tachykinin function in the basal ganglia. Brain Research, 1993, 632, 21-28.	1.1	13
195	Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. Brain Research, 1995, 700, 115-120.	1.1	13
196	Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies. Movement Disorders, 2006, 21, 970-975.	2.2	13
197	Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. Movement Disorders, 2021, 36, 389-397.	2.2	13
198	Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience, 2000, 98, 61-67.	1.1	12

#	ARTICLE	IF	CITATIONS
199	Developments in neuroimaging: positron emission tomography. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S180-S183.	1.1	12
200	The role of biomarkers and imaging in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 187-203.	1.4	12
201	Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 607-611.	0.8	12
202	Controlling for Cerebral Atrophy in Positron Emission Tomography Data. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1987, 7, 510-512.	2.4	11
203	Prevention and Management of Late Stage Complications in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1992, 19, 113-116.	0.3	11
204	Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. <i>Neuroscience</i> , 2002, 112, 261-266.	1.1	11
205	Is there seasonal variation in risk of Parkinson's disease?. <i>Movement Disorders</i> , 2007, 22, 1097-1101.	2.2	11
206	Imaging neural correlates of mild cognitive impairment in Parkinson's disease. <i>Lancet Neurology</i> , The, 2012, 11, 653-655.	4.9	11
207	Central pharmacokinetics of levodopa: Lessons from imaging studies. <i>Movement Disorders</i> , 2015, 30, 73-79.	2.2	11
208	Movement disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 136, 957-969.	1.0	11
209	Decisions under risk in Parkinson's disease: Preserved evaluation of probability and magnitude. <i>Neuropsychologia</i> , 2013, 51, 2679-2689.	0.7	10
210	Imaging in multiple system atrophy. <i>Neurology and Clinical Neuroscience</i> , 2014, 2, 178-187.	0.2	10
211	Dyskinesias and levodopa therapy: why wait?. <i>Journal of Neural Transmission</i> , 2018, 125, 1119-1130.	1.4	10
212	Milestones in neuroimaging. <i>Movement Disorders</i> , 2011, 26, 868-978.	2.2	9
213	Ethical and Clinical Considerations at the Intersection of Functional Neuroimaging and Disorders of Consciousness. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2016, 25, 613-622.	0.5	9
214	Optical coherence tomography of patients with Parkinson's disease and progressive supranuclear palsy. <i>Clinical Neurology and Neurosurgery</i> , 2020, 189, 105635.	0.6	9
215	Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. <i>European Journal of Pharmacology</i> , 1996, 298, 7-15.	1.7	8
216	Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2001, 8, 51-56.	1.1	8

#	ARTICLE	IF	CITATIONS
217	Continuous dopaminergic therapy in Parkinson disease: Time to stride back?. <i>Annals of Neurology</i> , 2010, 68, 3-5.	2.8	8
218	Canadian Perspectives on the Clinical Actionability of Neuroimaging in Disorders of Consciousness. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 96-105.	0.3	8
219	Dementia in Movement Disorders. <i>Canadian Journal of Neurological Sciences</i> , 1986, 13, 546-558.	0.3	7
220	Differential Diagnosis of Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, S1-S4.	0.3	7
221	Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?. <i>Nature Clinical Practice Neurology</i> , 2009, 5, 10-11.	2.7	7
222	Salivary gland biopsy for diagnosis of Parkinson's disease?. <i>Lancet Neurology</i> , The, 2016, 15, 654-656.	4.9	7
223	Tau imaging in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 91-93.	2.2	7
224	PBB3 binding in a patient with corticobasal syndrome. <i>Movement Disorders</i> , 2018, 33, 1359-1360.	2.2	7
225	Effect of age on caudate dopaminergic function in idiopathic Parkinsonism. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 1-5.	1.1	6
226	Assessing the integrity of the dopamine system in Parkinson's disease: How best to do it?. <i>Movement Disorders</i> , 2001, 16, 804-806.	2.2	6
227	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1129-1134.	1.1	6
228	PET Molecular Imaging in Familial Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 142, 177-223.	0.9	6
229	Striatal DAT SPECT: Caveat Emptor!. <i>Movement Disorders</i> , 2019, 34, 1430-1432.	2.2	6
230	Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy. <i>Neuropharmacology</i> , 1993, 32, 555-560.	2.0	5
231	The Neurotensin Antagonist SR 48692 Fails to Modify the Behavioural Responses to a Dopamine D1 Receptor Agonist in the Rat. <i>Neuropharmacology</i> , 1997, 36, 93-99.	2.0	5
232	Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum. <i>Neuroscience</i> , 1997, 76, 1173-1185.	1.1	5
233	Treatment for the progression of Parkinson's disease. <i>Lancet Neurology</i> , The, 2005, 4, 206.	4.9	5
234	Joubert syndrome surviving to adulthood associated with a progressive movement disorder. <i>Movement Disorders</i> , 2007, 22, 262-264.	2.2	5

#	ARTICLE	IF	CITATIONS
235	Effects of ethanol in a putative rodent model of tardive dyskinesia. <i>Pharmacology Biochemistry and Behavior</i> , 1996, 54, 541-546.	1.3	4
236	The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCKA receptor antagonist: Evidence for a novel CCK receptor subtype?. <i>Neuropharmacology</i> , 1997, 36, 1679-1688.	2.0	4
237	Agonizing over dopaminergic replacement therapyâ€™ lessons from animal models of parkinsonâ€™s disease. <i>Experimental Neurology</i> , 2003, 183, 1-3.	2.0	4
238	Impact of the Spatial Normalization Template and Realignment Procedure on the SPM Analysis of [¹¹ C]Raclopride PET Studies. <i>IEEE Transactions on Nuclear Science</i> , 2004, 51, 205-211.	1.2	4
239	Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 277-286.	0.3	4
240	Challenges and unfulfilled promises in Parkinson's disease. <i>Lancet Neurology</i> , The, 2017, 16, 866-867.	4.9	4
241	Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson's disease: Application of dynamic mode decomposition to PET. <i>NeuroImage: Clinical</i> , 2020, 25, 102150.	1.4	4
242	Neuroimaging of Sleep and Sleep Disorders. , 2013, , .		4
243	Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade. <i>Parkinsonism and Related Disorders</i> , 1996, 2, 167-175.	1.1	3
244	Pharmacodynamic modeling of oral levodopa in Parkinson's disease. <i>Annals of Neurology</i> , 2001, 50, 687-688.	2.8	3
245	Hot spots: Can positron emission tomography offer insights into the pathogenesis of PD?. <i>Annals of Neurology</i> , 2005, 57, 161-162.	2.8	3
246	Movement disorders: new insights into Parkinson's disease. <i>Lancet Neurology</i> , The, 2011, 10, 5-7.	4.9	3
247	Comment: Increased D ₃ bindingâ€™ A substrate for levodopa-induced dyskinesias?. <i>Neurology</i> , 2016, 86, 228-228.	1.5	3
248	Neurology in Canada: History of the Canadian Neurological Society. <i>Neurology</i> , 2013, 80, 406-408.	1.5	2
249	Imaging in Parkinsonâ€™s disease: time to look below the neck. <i>Brain</i> , 2015, 138, 512-514.	3.7	2
250	Occult central pontine myelinolysis post liver transplant: A consequence of pre-transplant hyponatremia. <i>Annals of Hepatology</i> , 2019, 18, 651-654.	0.6	2
251	Deception and the ethics of placebo. <i>International Review of Neurobiology</i> , 2020, 153, 147-163.	0.9	2
252	Positron Emission Tomography in Parkinsonâ€™s Disease. , 2005, , 25-35.		2

#	ARTICLE	IF	CITATIONS
253	A brain network response to sham surgery. <i>Journal of Clinical Investigation</i> , 2014, 124, 3285-3288.	3.9	2
254	What's New at the Journal in 2022. <i>Movement Disorders</i> , 2022, 37, 1-2.	2.2	2
255	Ethical Issues In The Management Of Parkinson's Disease. , 2011, , .		1
256	Liquid Xenon Detectors for Positron Emission Tomography. <i>Journal of Physics: Conference Series</i> , 2011, 312, 062006.	0.3	1
257	Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 189-194.	1.1	1
258	<i>Movement Disorders</i> Journal: Yesterday, Today, Tomorrow, and Always. <i>Movement Disorders</i> , 2019, 34, 1814-1816.	2.2	1
259	Antisense strategies for the treatment of neurological disease. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 547-562.	2.4	0
260	“Stiff in the Closet”- Who Provides Care for Parkinsonian Patients?. <i>Canadian Journal of Neurological Sciences</i> , 2002, 29, 203-204.	0.3	0
261	On the Use of Clusters to Determine Environmental Influence on Disease”Reply. <i>Archives of Neurology</i> , 2005, 62, 331.	4.9	0
262	Neuroimaging of Parkinson's disease. , 2010, , 361-370.		0
263	Parkin and Parkinson's disease: Differentiated by non-dopaminergic dysfunction?. <i>Experimental Neurology</i> , 2010, 225, 48-50.	2.0	0
264	Neuroimaging of Parkinson's disease and multiple system atrophy in patients with sleep disturbance. , 0, , 305-315.		0
265	Imaging of Dopamine and Serotonin Receptors and Transporters. , 2014, , 241-264.		0
266	The Saskatchewan Movement Disorders Program: Commitment Pays Off. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 70-71.	0.3	0
267	Raul de la Fuente-Fernandez, February 22, 1959–May 11, 2016. <i>Movement Disorders</i> , 2016, 31, 1144-1145.	2.2	0
268	Reply to letter to the editor: Is there anything more to learn from SWEDD?. <i>Movement Disorders</i> , 2016, 31, 1426-1428.	2.2	0
269	Operationalizing Neuroimaging for Disorders of Consciousness in the Canadian Context. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 633-635.	0.3	0
270	Conclusions. <i>Movement Disorders</i> , 2018, 33, 701-701.	2.2	0

#	ARTICLE	IF	CITATIONS
271	Immunotherapy for Parkinson's disease: stay tuned. <i>Lancet Neurology</i> , The, 2020, 19, 561-562.	4.9	0
272	2021: Looking Forward. <i>Movement Disorders</i> , 2021, 36, 11-12.	2.2	0
273	Advances in the Role of Neuroimaging to Monitor Disease Progression in Parkinsonâ€™s Disease. <i>European Neurological Review</i> , 2011, 6, 161.	0.5	0
274	Dopaminergic Imaging in Parkinsonâ€™s Disease: PET. , 2011, , 3-10.		0
275	Insights into LRRK2-Mutation Related PD from PET Imaging Studies. , 2014, , 123-124.		0
276	Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis. , 2014, , 161.		0
277	LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism. , 2008, , 75-89.		0
278	Cortical morphology predicts placebo response in multiple sclerosis. <i>Scientific Reports</i> , 2022, 12, 732.	1.6	0
279	Imaging of the Parkinsonian Brain in Relation to Restorative Therapy. , 2006, , 119-130.		0